Clinical trial
Vaccine Therapy in Treating Patients With Melanoma of the Eye
NCT00036816 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Terminated
Key facts
| NCT number | NCT00036816 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Melanoma of the Eye |
| Official title | Randomized Phase III Study Of Adjuvant Immunization With The NA17.A2 And Melanoma Differentiation Peptites In HLA-A2 Patients With Primary Ocular Melanoma At High Risk Of Relapse |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Intraocular Melanoma |
| Intervention type | Biological |
| Interventions | MART-1 antigen, NA17-A antigen, gp100 antigen, tyrosinase peptide |
| Enrollment | 13 |
| Start date | Feb 1, 2002 |
| Primary completion | Feb 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Sep 24, 2012 |
| Countries | Belgium, Denmark |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: